Cargando…

Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach

BACKGROUND: Interstitial fibrosis is involved in the progression of various chronic kidney diseases and renal failure. Diosmin is a naturally occurring flavonoid glycoside that has antioxidant, anti-inflammatory, and antifibrotic activities. However, whether diosmin protects kidneys by inhibiting re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Wen-Man, Wang, Zhi-Juan, Shi, Rui, Zhu, Yuyu, Li, Xun-Liang, Wang, De-Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182711/
https://www.ncbi.nlm.nih.gov/pubmed/37179298
http://dx.doi.org/10.1186/s12906-023-03976-z
_version_ 1785041810383437824
author Zhao, Wen-Man
Wang, Zhi-Juan
Shi, Rui
Zhu, Yuyu
Li, Xun-Liang
Wang, De-Guang
author_facet Zhao, Wen-Man
Wang, Zhi-Juan
Shi, Rui
Zhu, Yuyu
Li, Xun-Liang
Wang, De-Guang
author_sort Zhao, Wen-Man
collection PubMed
description BACKGROUND: Interstitial fibrosis is involved in the progression of various chronic kidney diseases and renal failure. Diosmin is a naturally occurring flavonoid glycoside that has antioxidant, anti-inflammatory, and antifibrotic activities. However, whether diosmin protects kidneys by inhibiting renal fibrosis is unknown. METHODS: The molecular formula of diosmin was obtained, targets related to diosmin and renal fibrosis were screened, and interactions among overlapping genes were analyzed. Overlapping genes were used for gene function and KEGG pathway enrichment analysis. TGF-β1 was used to induce fibrosis in HK-2 cells, and diosmin treatment was administered. The expression levels of relevant mRNA were then detected. RESULTS: Network analysis identified 295 potential target genes for diosmin, 6828 for renal fibrosis, and 150 hub genes. Protein–protein interaction network results showed that CASP3, SRC, ANXA5, MMP9, HSP90AA1, IGF1, RHOA, ESR1, EGFR, and CDC42 were identified as key therapeutic targets. GO analysis revealed that these key targets may be involved in the negative regulation of apoptosis and protein phosphorylation. KEGG indicated that pathways in cancer, MAPK signaling pathway, Ras signaling pathway, PI3K-Akt signaling pathway, and HIF-1 signaling pathway were key pathways for renal fibrosis treatment. Molecular docking results showed that CASP3, ANXA5, MMP9, and HSP90AA1 stably bind to diosmin. Diosmin treatment inhibited the protein and mRNA levels of CASP3, MMP9, ANXA5, and HSP90AA1. Network pharmacology analysis and experimental results suggest that diosmin ameliorates renal fibrosis by decreasing the expression of CASP3, ANXA5, MMP9, and HSP90AA1. CONCLUSIONS: Diosmin has a potential multi-component, multi-target, and multi-pathway molecular mechanism of action in the treatment of renal fibrosis. CASP3, MMP9, ANXA5, and HSP90AA1 might be the most important direct targets of diosmin.
format Online
Article
Text
id pubmed-10182711
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101827112023-05-14 Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach Zhao, Wen-Man Wang, Zhi-Juan Shi, Rui Zhu, Yuyu Li, Xun-Liang Wang, De-Guang BMC Complement Med Ther Research BACKGROUND: Interstitial fibrosis is involved in the progression of various chronic kidney diseases and renal failure. Diosmin is a naturally occurring flavonoid glycoside that has antioxidant, anti-inflammatory, and antifibrotic activities. However, whether diosmin protects kidneys by inhibiting renal fibrosis is unknown. METHODS: The molecular formula of diosmin was obtained, targets related to diosmin and renal fibrosis were screened, and interactions among overlapping genes were analyzed. Overlapping genes were used for gene function and KEGG pathway enrichment analysis. TGF-β1 was used to induce fibrosis in HK-2 cells, and diosmin treatment was administered. The expression levels of relevant mRNA were then detected. RESULTS: Network analysis identified 295 potential target genes for diosmin, 6828 for renal fibrosis, and 150 hub genes. Protein–protein interaction network results showed that CASP3, SRC, ANXA5, MMP9, HSP90AA1, IGF1, RHOA, ESR1, EGFR, and CDC42 were identified as key therapeutic targets. GO analysis revealed that these key targets may be involved in the negative regulation of apoptosis and protein phosphorylation. KEGG indicated that pathways in cancer, MAPK signaling pathway, Ras signaling pathway, PI3K-Akt signaling pathway, and HIF-1 signaling pathway were key pathways for renal fibrosis treatment. Molecular docking results showed that CASP3, ANXA5, MMP9, and HSP90AA1 stably bind to diosmin. Diosmin treatment inhibited the protein and mRNA levels of CASP3, MMP9, ANXA5, and HSP90AA1. Network pharmacology analysis and experimental results suggest that diosmin ameliorates renal fibrosis by decreasing the expression of CASP3, ANXA5, MMP9, and HSP90AA1. CONCLUSIONS: Diosmin has a potential multi-component, multi-target, and multi-pathway molecular mechanism of action in the treatment of renal fibrosis. CASP3, MMP9, ANXA5, and HSP90AA1 might be the most important direct targets of diosmin. BioMed Central 2023-05-13 /pmc/articles/PMC10182711/ /pubmed/37179298 http://dx.doi.org/10.1186/s12906-023-03976-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhao, Wen-Man
Wang, Zhi-Juan
Shi, Rui
Zhu, Yuyu
Li, Xun-Liang
Wang, De-Guang
Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach
title Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach
title_full Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach
title_fullStr Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach
title_full_unstemmed Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach
title_short Analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach
title_sort analysis of the potential biological mechanisms of diosmin against renal fibrosis based on network pharmacology and molecular docking approach
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182711/
https://www.ncbi.nlm.nih.gov/pubmed/37179298
http://dx.doi.org/10.1186/s12906-023-03976-z
work_keys_str_mv AT zhaowenman analysisofthepotentialbiologicalmechanismsofdiosminagainstrenalfibrosisbasedonnetworkpharmacologyandmoleculardockingapproach
AT wangzhijuan analysisofthepotentialbiologicalmechanismsofdiosminagainstrenalfibrosisbasedonnetworkpharmacologyandmoleculardockingapproach
AT shirui analysisofthepotentialbiologicalmechanismsofdiosminagainstrenalfibrosisbasedonnetworkpharmacologyandmoleculardockingapproach
AT zhuyuyu analysisofthepotentialbiologicalmechanismsofdiosminagainstrenalfibrosisbasedonnetworkpharmacologyandmoleculardockingapproach
AT lixunliang analysisofthepotentialbiologicalmechanismsofdiosminagainstrenalfibrosisbasedonnetworkpharmacologyandmoleculardockingapproach
AT wangdeguang analysisofthepotentialbiologicalmechanismsofdiosminagainstrenalfibrosisbasedonnetworkpharmacologyandmoleculardockingapproach